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Background: Complement receptor 1 (CR1), the receptor for C3b/C4b complement peptides, plays a crucial role in
carcinogenesis. However, the association of genetic variants of CR1 with susceptibility to lung cancer remains
unexplored.
Methods: This case-control study included 470 non-small cell lung cancer (NSCLC) patients and 470 cancer-free
controls. Based on the Chinese population data from HapMap database, we used Haploview 4.2 program to select
candidate tag SNPs. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed by logistic regression to
evaluate the association of each tag SNP with NSCLC.
Results: Multivariate regression analysis indicated that the rs7525160 CC genotype was associated with an
increased risk of developing NSCLC (OR = 1.52, 95% CI = 1.02-2.28; P = 0.028) compared with the GG genotype.
When stratified by smoking status, the risk of NSCLC was associated with the rs7525160 C allele carriers in smokers
with OR (95% CI) of 1.72 (1.15-2.79), but not in non-smokers with OR (95% CI) of 1.15 (0.81-1.65). When the
interaction between smoking status and rs7525160 G > C variant was analyzed with cumulative smoking dose
(pack-year). Similarly, GC or CC genotype carriers have increased risk of NSCLC among heavy smokers (pack-year≥ 25)
with OR (95% CI) of 2.01 (1.26-3.20), but not among light smokers (pack-year <25) with OR (95% CI) of 1.32 (0.81-2.16).
Conclusion: CR1 rs7525160 G > C polymorphism was associated with an increased risk of developing NSCLC in
Chinese population. The association displays a manner of gene-environmental interaction between CR1 rs7525160
tagSNP and smoking status.
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The complement system plays a critical role in the process
of carcinogenesis. Despite of significant research, contro-
versial viewpoints remain on the exact relationship of
complement system with cancer. Classically, the comple-
ment system fights against cancer by exerting the effects
of immunosurveillance in the immunologic microenviron-
ment of tumors [1]. Recently it was found that comple-
ment may contribute to tumor growth by a wide variety of
mechanisms including dysregulation of mitogenic signal-
ing pathways, sustained cellular proliferation, angiogen-
esis, insensitivity to apoptosis, invasion and migration, and
escape from complement cytotoxicity [2]. This suggested
complement, just like a double-edged sword, plays a dual* Correspondence: jyxuemei@gmail.com
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unless otherwise stated.role in carcinogenesis. In particular, component C3 and its
receptors have been demonstrated to be a key link be-
tween innate and adaptive immunity [3].
Complement receptor type 1 (CR1, CD35) is a multi-
functional polymorphic glycoprotein which binds to C3b
fragment of C3 and to C4b with lower affinity [4,5]. CR1
belongs to the regulators of complement activation (RCA)
family of proteins and is expressed in a wide spectrum of
cells and involved in T-cell and B-cell mediated immune
regulation [6,7]. CR1 also modulates the complement cas-
cade activation by preventing formation of classical and
alternative pathway convertases and by acting as a cofac-
tor for factor I mediated inactivation of C3b and C4b
[8,9]. It has been demonstrated that chronic inflammation
can predispose to cancer development and spread [10], as
a fundamental component of innate immunity, the com-
plement cascade consists of potential proinflammatoryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Distributions of select characteristics in cases and
control subjects
Variables Cases (n = 470) Controls (n = 470)
No (%) No (%) Pa
Sex 0.832
Male 324 68.9 328 69.8
Female 146 31.1 142 30.2
Age 0.470
<50 84 17.9 96 20.4
50-59 177 37.7 187 39.8
60-69 129 27.4 111 23.6
≥70 80 17.0 76 16.2
Smoking status 0.321
Non-smoker 265 56.4 281 59.8
Smoker 205 43.6 189 40.2
Pack-year smoked 0.001
<25 75 36.6 96 50.8
≥25 130 63.4 93 49.2
aTwo-sided χ2 test.
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activation and abnormal expression in tumor tissues has
been demonstrated [11]. Considering the important role
of CR1 in complement activation, innate immunity and
chronic inflammation, CR1 has emerged as a molecule of
immense interest in gaining insight into the susceptibility
to cancer.
CR1 gene is located on the Chromosome 1 at the locus
1q32 [12]. Various polymorphisms have been studied in-
cluding the intronic and exonic density polymorphism
for their ability to alter the density of erythrocyte CR1
on the cell membranes [13-15]. There are also the mo-
lecular weight variants due to insertion-deletion poly-
morphisms [16]. Up to now, there have been very few
studies on the association of genetic variants of CR1
with susceptibility to autoimmune and inflammatory
diseases. It has been proposed that genetic variant at
CR1 gene (rs6656401) might influence the susceptibility
to late-onset Alzheimer’s disease [17]. CR1 expression
in Peripheral Blood Mononuclear Cells (PBMCs) may
be a new biomarker for prognosis of nasopharyngeal
carcinoma and a potential therapeutic target [18].
Recently, it has been indicated that CR1 A3650G
(His1208Arg) polymorphism plays a critical role in
conferring genetic susceptibility to gallbladder cancer
in north Indian population [19]. However, the associ-
ation of genetic variants of CR1 with risk of lung can-
cer remains unexplored.
Worldwide, lung cancer is the most common cancer
in terms of both incidence and mortality [20]. NSCLC is
the most common subtype of lung cancer and less ag-
gressive and metastic than SCLC. Although cigarette
smoking is the predominant risk factor for lung cancer,
inherited genetic characteristics are presumed to account
in part for this interindividual variation in lung cancer
susceptibility. Recently, several genome-wide association
studies have demonstrated the common genetic variations
associated with susceptibility to lung cancer [21-24].
Given the involvement of the complement system in co-
ordinating innate immunity and inflammatory response
[25], further examination of the potential association
between genetic variation of CR1 genes and lung cancer
is warranted.
In the current study, we conducted a case-control study
to investigate the association of tag SNPs in CR1 gene
with the risk of NSCLC and effect of the interaction of
gene-environment on the risk of NSCLC.
Results
Subject characteristics
The frequency distributions of select characteristics in
cases and control subjects were shown in Table 1. The
mean age (±SD) was 59.6 ± 10.5 years for the cancer pa-
tients and 57.2 ± 13.3 years for the controls. No significantdifference was found in the mean age between cases and
controls (P = 0.470). There was no significant difference in
proportion of sex and smoking status between cases and
controls (P = 0.832 and P = 0.321, respectively). However,
there was significant difference between cases and con-
trols when compared by pack-year smoked (P = 0.001).
The heavy smokers (≥25 pack-year) accounted for 61.5%
in cases but only 45.5% in controls, which suggested that
cigarette smoking was a prominent contributor to the risk
of lung cancer. Of the 470 case patients, 178 (37.9%) were
diagnosed as adenocarcinoma, 238 (50.6%) as squamous
cell carcinoma, and 100 (%) as other types, including large
cell carcinoma (n = 49) and mixed cell carcinoma (n = 5).
Association of CR1 tag SNP with NSCLC risk
Total 13 selected tag SNPs of CR1 in HapMap database
among Chinese population were analyzed. Except for
rs9429782 polymorphism, the genotype distributions
of other SNPs in controls were consistent to Hardy-
Weinberg equilibrium. Therefore, we excluded the
rs9429782 from further analysis. In order to screen the
genetic variants that confer the susceptibility to lung
cancer, 12 candidate tagSNPs were genotyped in a case-
control study consisting of 470 lung cancer patients and
470 cancer-free controls as shown in Table 2. Import-
antly, genotype frequency of one intronic SNP
(rs7525160 G > C) in cases was found to be significantly
different from those of controls (χ2 = 6.339, P=0.042).
Further multivariate regression model with adjustment
for age, gender, and smoking status was used to assess
the association between rs7525160 G > C polymorphism
Table 2 Genotype frequencies of CRI among cases and







(n = 470) OR (95% CI)* P
No (%) No (%)
rs7525160
GG 176 37.5 139 29.6 1.00 (ref.)
CG 228 48.5 256 54.5 1.38 (1.04-1.85) 0.041
CC 66 14.0 75 15.9 1.52 (1.02-2.28) 0.028
rs3886100
GG 117 24.9 105 22.4 1.00 (ref.)
AG 223 47.4 253 53.8 1.33 (0.97-1.81) 0.078
AA 130 27.7 112 23.8 1.06 (0.73-1.54) 0.755
rs11118167
TT 348 74.1 353 75.1 1.00 (ref.)
CT 111 23.6 102 21.7 0.89 (0.65-1.21) 0.457
CC 11 2.3 15 3.2 1.35 (0.61-3.01) 0.461
rs9429782
GG 250 53.2 261 55.5 1.00 (ref.)
GT 220 46.8 209 44.5 0.89 (0.69-1.16) 0.388
rs10494885
CC 178 37.9 164 34.9 1.00 (ref.)
CT 224 47.6 232 49.4 1.11 (0.83-1.47) 0.490
TT 68 14.5 74 15.7 1.20 (0.81-1.78) 0.365
rs7542544
CC 128 27.2 108 23.0 1.00 (ref.)
AC 223 47.5 252 53.6 1.21 (0.88-1.67) 0.239
AA 119 25.3 110 23.4 0.90 (0.62-1.30) 0.897
rs6691117
AA 324 68.9 327 69.6 1.00 (ref.)
AG 131 27.9 128 27.2 0.98 (0.73-1.31) 0.888
GG 15 3.2 15 3.2 0.96 (0.46-2.02) 0.923
rs6656401
GG 436 92.8 447 95.1 1.00 (ref.)
AG 34 7.2 23 4.9 0.68 (0.39-1.18) 0.174
AA 0 0.0 0 0.0 NC§
rs2296160
CC 185 39.4 194 41.3 1.00 (ref.)
CT 226 48.1 220 46.8 0.91 (0.69-1.21) 0.521
TT 59 12.5 56 11.9 0.90 (0.59-1.37) 0.606
rs9429942
TT 452 96.2 457 97.2 1.00 (ref.)
CT 18 3.8 13 2.8 0.77 (0.37-1.61) 0.482
CC 0 0.0 0 0.0 NC§
Table 2 Genotype frequencies of CRI among cases and
controls and their association with non-small cell lung
cancers (Continued)
rs4844600
GG 171 36.4 179 38.1 1.00 (ref.)
AG 230 48.9 228 48.5 0.92 (0.70-1.22) 0.571
AA 69 14.7 63 13.4 0.87 (0.58-1.31) 0.513
rs3818361
CC 187 39.8 188 40.0 1.00 (ref.)
CT 224 47.7 224 47.7 0.98 (0.74-1.29) 0.868
TT 59 12.5 58 12.3 0.96 (0.63-1.46) 0.848
rs17048010
TT 301 64.0 286 60.8 1.00 (ref.)
CT 154 32.8 164 34.9 1.09 (0.82-1.43) 0.556
CC 15 3.2 20 4.3 1.40 (0.70-2.79) 0.343
*Adjusted by age, sex and smoking status; §NC, not calculated.
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rs7525160 CC genotype was associated with an in-
creased risk of developing NSCLC with OR (95% CI)
of 1.52 (1.02-2.28) compared with the GG genotype.
Other tagSNPs of CR1 were not significantly associ-
ated with the risk of NSCLC in our study population
(P >0.05).
Generalized Multifactor Dimensionality Reduction
(GMDR) was used to evaluate gene-gene interaction.
The summary of gene-gene interaction models is listed
in Table 3. The SNP rs7525160 in CR1 had the highest
testing balanced accuracy among 12 SNPs. The three-
way interaction model among rs4844600, rs10494885
and rs7525160 showed high testing balance accuracy
and cross validation consistency, but the testing bal-
anced accuracy was lower than the two-way gene-gene
interaction in NSCLC. For each model, the interaction
was not significant (P > 0.05).
Interaction of CR1 SNP with smoking
Cigarette smoking is a well-known risk for lung cancer,
so stratification by smoking status was performed to in-
vestigate the association of rs7525160 G > C variant with
the risk of NSCLC. As shown in Table 4, the risk of
NSCLC was associated with the rs7525160 C allele car-
riers in smokers with OR (95% CI) of 1.72 (1.15-2.59), but
not in non-smokers with OR (95% CI) of 1.15 (0.81-1.65),
suggesting that the CR1 rs7525160 G > C polymorphism
is a smoking-modifying risk factor for susceptibility to
NSCLC. When the interaction between smoking status
and rs7525160 G > C variant was analyzed with cumula-
tive smoking dose (pack-year), consistently, GC or CC
genotype carriers have increased risk of NSCLC among
heavy smokers (pack-year ≥ 25) with OR (95% CI) of 2.01
(1.26-3.20), but not among light smokers (pack-year <25)
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erogeneity of the stratification analysis by smoking status
is 0.015. However, the P value for interaction between
rs7525160 polymorphism and smoking is 0.172 and the
power for the interaction is 0.49.Discussion
The chronic airway inflammation and dysfunctional im-
mune system might promote pulmonary carcinogenesis.
Implicated in the immune and inflammatory responses,
the complement cascade plays a pivotal role in the de-
velopment of cancer. Thus, it is likely that the genetic
variants of CR1 in the complement system confer the
susceptibility to lung cancer. In this study, we have for
the first time demonstrated that one intronic SNP
(rs7525160 G > C) out of 13 tag SNPs of CR1 was associ-
ated with the risk of NSCLC in Chinese population. Not-
ably, the rs7525160 CC genotype was associated with
an increased risk of developing NSCLC (OR = 1.52, 95%
CI = 1.02-2.28; P = 0.028) compared with the GG genotype.
MDR analysis also showed that there was no gene-gene
interaction among 12 tag SNPs in CR1 gene. Moreover,
the risk of NSCLC was associated with the rs7525160 C
allele carriers in smokers with OR (95% CI) of 1.72
(1.15-2.59), but not in non-smokers with OR (95% CI)
of 1.15 (0.81-1.65), indicating this SNP is a smoking-
modifying risk factor for susceptibility to NSCLC. To
the best of our knowledge, this study shed new insight
into the interplay of genetic variation of CR1 with lung
cancer risk. More importantly, it highlights the poten-
tial gene-environmental interaction influences the sus-
ceptibility to lung cancer.Table 4 Risk of CR1 genotypes with NSCLC by smoking status
Smoking
status GG* OR (95% CI)§ P v
Non-smoker 84/99 1.00 (reference)
Smoker 55/77 0.86 (0.54-1.38) 0.5
<25 pack-years 19/41 0.59 (0.31-1.10) 0.0
≥25 pack-years 36/36 1.18 (0.67-2.08) 0.5
*Number of cases/number of controls.
§Data were calculated by logistic regression and adjusted for age and gender.The complement system has been proposed to get in-
volved in innate immunity with the ability to “comple-
ment” antibody-mediated elimination of immune complex
and foreign pathogens [26]. Upon complement activation,
the biologically active peptides C5a and C3a elicit a lot of
pro-inflammatory effects and could be closely associated
with tumorigenesis [27]. Complement proteins play a dual
role in the tumor microenvironment. On one hand, they
exert a defensive effect against tumor through comple-
ment or antibody-dependent cytotoxicity [1,28]. On the
other hand, they may escape from immunosurveillance
and facilitate carcinogenesis [2]. Specifically, a number of
experimental evidence has suggested an association be-
tween complement activation and tumor growth [29,30],
which provides a strong biologically link between the
abnormal expression and activity of complement cas-
cade and carcinogenesis.
Till now, a few studies have been carried out to demon-
strate the association of genetic variants in complement
proteins with susceptibility to cancer. A significant associ-
ation of CR2 SNP (rs3813946) with the development of
nasopharyngeal carcinoma was indicated in Cantonese
population [31], and the genetic variations of complement
system genes C5 and C9 plays a potential role in suscepti-
bility to non-Hodgkin lymphoma (NHL) [32]. Recently, it
has been shown that complement factor H Y402H poly-
morphism interact with cigarette smoking to confer the
susceptibility to lung cancer [33]. Furthermore, it has been
indicated that CR1 A3650G (His1208Arg) polymorphism
plays a critical role in conferring genetic susceptibility
to gallbladder cancer in north Indian population [19].
However, whether the genetic variants of CR1 are re-
lated to the risk of lung cancer remains unknown. In
this case-control study, we found an intronic SNP
(rs7525160 G > C) with CC genotype was significantly
associated with an increased risk of NSCLC. Consist-
ently, our results were in accordance with the study that
genetic polymorphisms in innate immunity genes may
play a role in the carcinogenesis of lung cancer [34]. It
is likely that some genetic variations in strong link dis-
equilibrium with this intronic SNP (rs7525160 G > C)
are functional, which provides a new insight into the
hallmarks in susceptibility to lung cancer and furtherCR1 genotype
alue CG + CC* OR (95% CI)§ P value
181/182 1.15 (0.81-1.65) 0.440
28 150/112 1.72 (1.15-2.59) 0.009
99 56/55 1.32 (0.81-2.61) 0.266
62 94/57 2.01 (1.26-3.20) 0.003
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proposal.
Functionally, human CR1 exists on the surface of al-
most all peripheral blood cells and plays a key role in
immune complex clearance and complement inhibition
at the cell surface by binding to activated products C3b
and C4b [4,35]. CR1 also possesses cofactor activity for
the serum protease factor I and is thus involved in the
generation of further fragments of C3/4b with the acti-
vation of complement cascade and the cellular immune
response [4]. In our study, the association of CR1 poly-
morphism with lung cancer is biologically plausible in
that the intronic polymorphism could affect the density
of CR1 molecules on the cell surface, thereby contribut-
ing to autoimmune disorders and neoplasm.
Tobacco smoking is an established risk factor for sus-
ceptibility to lung cancer. However, not all people who
suffer from lung cancer are smokers. Lung cancer in
non-smokers can be induced by second hand smoke, air
pollutants and diesel exhaust [36-39]. Our present data
showed significant difference of pack-year smoked, but
not smoking status between NSCLC cases and controls,
which suggested the important role of other environ-
mental factors in the development of NSCLC. Tobacco
could induce chronic and sustained inflammation in
lung microenvironment, contributing to pulmonary car-
cinogenesis in smokers [40]. Support also comes from
the epidemiologic data regarding inflammation and lung
cancer [41]. CR1, an important molecule implicated in
immunity and inflammation, could protect the host from
invasion of exogenous chemicals derived from cigarette
smoking. Genetic variant of CR1 could alter gene func-
tion and result in deregulation of the inflammatory and
immune responses, thereby, modulating the suscepti-
bility to lung cancer. More importantly, we observedTable 5 Primers used in this study
SNP_ID Alleles 1st-PCR primer sequences 2n
rs7525160 G/C ACGTTGGATGCAAAATCAAGGTTTAAAGTC ACGTTG
rs3886100 G/A ACGTTGGATGGGCCTCAGATCCTCAAAATC ACGTTG
rs11118167 T/C ACGTTGGATGATGTGTGTAGTCACTTAGCC ACGTTG
rs9429782 G/T ACGTTGGATGACACGCGGGATCCATCGGAA ACGTTG
rs10494885 C/T ACGTTGGATGGTGTAATGCCACAGACATGC ACGTTG
rs7542544 C/A ACGTTGGATGGCTAAGAGCCATTAGTGTGC ACGTTGG
rs6691117 A/G ACGTTGGATGAGAGTACCAGGAAACAGGAG ACGTTG
rs6656401 G/A ACGTTGGATGAAAGGACACACACAGAGGAG ACGTTG
rs2296160 C/T ACGTTGGATGCCAGAATTCCTCAGCAAAAC ACGTTG
rs9429942 T/C ACGTTGGATGTACATGTGCACAACGTGCAG ACGTTGG
rs4844600 G/A ACGTTGGATGGAATGGCTTCCATTTGCCAG ACGTTG
rs3818361 C/T ACGTTGGATGTGGAAAGGACAGTTCCAGAG ACGTTG
rs17048010 T/C ACGTTGGATGTTTCAAGGCTGCTCCTTGTT ACGTTGa potential interaction of this SNP (rs7525160 G > C)
with smoking status, suggesting the gene-environmental
interaction plays a prominent role in the susceptibility to
lung cancer. Our present study has its limitation. Our
patients may not be representative of total NSCLC pa-
tients at large because they were recruited from only
one hospital. In addition, due to the relatively small sam-
ple size, further case-control studies are still needed to
replicate and extend our findings.Conclusion
We conducted a case-control study in Chinese subjects
and found an intronic SNP (rs7525160 G > C) of CR1
was significantly associated with lung cancer risk. To the
best of our knowledge, this study provides the first evi-
dence that genetic variant of CR1 (rs7525160 G > C) was
a smoking-modifying contributor to the development of
lung cancer.Methods
Study subjects
This case-control study consisted of 470 patients with
histopathologically confirmed NSCLC and 470 cancer-
free controls. All subjects were genetic unrelated ethnic
Han Chinese. Patients were recruited between January
2008 and December 2012 at Tangshan Gongren Hospital
(Tangshan, China). There were no age, gender or stage
restrictions, however, patients with previous malignancy
or metastasized cancer from other organs were excluded.
The response rate for patients was 94%. The controls
were randomly selected from a pool of a cancer-free
population from a nutritional survey conducted in the
same region. The selection criteria for control subjects
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the residential region; and iv) the time period for blood
sample collection. At recruitment, informed consent
was obtained from each subject, and each participant
was then interviewed to collect detailed information
on demographic characteristics. This study was approved
by the institutional review board of Hebei United
University.
Tag SNPs selection and genotyping
Based on the Chinese population data from HapMap
database, we used Haploview 4.2 program to select can-
didate tag SNPs with an r2 threshold of 0.80 and minor
allele frequency (MAF) greater than 1%. Furthermore,
we also added two potential functional polymorphisms,
rs9429942 and rs6691117 [42,43]. Therefore, we included
13 SNPs in our study, which represents common genetic
variants in Chinese population.
Genotyping was performed at Bomiao Tech (Beijing,
China) using iPlex Gold Genotyping Asssy and Sequenom
MassArray (Sequenom, San Diego, CA, USA). Sequenom’s
MassArray Designer was used to design PCR and exten-
sion primers for each SNP. Primer information for se-
lected tag SNPs was listed in Table 5.
Statistical analysis
We used Chi-square test to examine the differences in
the distributions of demographic characteristics, and
genotype frequencies between cases and controls. The
NSCLC risk associated with CR1 tag SNPs was esti-
mated as odds ratios (OR) and 95% confidence intervals
(CI) computed by logistic regression model adjusted for
age, gender, and smoking status where it was appropri-
ate. Smokers were considered current smokers if they
smoked up to 1 year before the date of cancer diagnosis
for NSCLC patients or before the date of the interview
for controls. The number of pack-years smoked was de-
termined as an indication of cumulative cigarette-dose
level [pack-year = (cigarettes per day/20) × (years smoked)].
Light and heavy smokers were categorized by using the
50th percentile pack-year value of the controls as the cut
points (i.e., ≤25 and >25 pack-years). All statistical tests
were 2 sided with P< 0.05 as the significant level. Statistical
analyses were done using SPSS (version 16.0, SPSS Inc,
Chicago, IL). Gene-gene and gene-smoking interactions
were analyzed by open-resource GMDR software package
(version 0.9) and Quanto (http://www.hydra.usc.edu/gxe)
[44,45].
Abbreviations
CR1: Complement receptor 1; OR: Odds ratio; CI: Confidence interval;
SNP: Single nucleotide polymorphism.
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